Back

National Association for Continuing Education

  • Diabetes Mellitus, Type 2
  • Heart Failure, Diastolic
  • Mineralocorticoid Receptor Antagonists
  • Renal Insufficiency, Chronic
  • Stroke Volume

From Gaps to Gains: Guiding HFmrEF and HFpEF Care

Heart failure with left ventricular ejection fraction (LVEF) 40% (HFmrEF and HFpEF) is an increasing public health challenge, with a lifetime risk of 24%. These subtypes are often difficult to diagnose and manage in primary care, especially in patients with obesity, type 2 diabetes, and chronic kidney disease, which contribute to poor outcomes and persistent cardiovascular risk. Although SGLT2 inhibitors and other therapies have improved care, important gaps remain in mortality reduction and symptom control. This educational initiative highlights the latest evidence, including the FINEARTS-HF trial and the role of the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone, which has been approved to reduce worsening heart failure events and cardiovascular death in patients with LVEF 40%. Participants will also gain practical guidance on initiating and monitoring MRA therapy, identifying contraindications, and optimizing individualized care plans.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 1 credit

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • Enduring / On-demand
  • Credit · Up to 1 credit
  • Commercial Support
  • Released
    Jun 22, 2026
  • Last day to claim credit
    Jun 23, 2027 8 months left